Analysis of Deals in Neurodegenerative Diseases published by PharmaVentures Ltd in July, 2010. This report price starts from US $ 3344.
Introduction
Abstract
This new report follows the highly acclaimed and popular report series on key
deal making therapy areas. It focuses on the five major neurodegenerative
diseases:
Alzheimer' s disease
Parkinson' s disease
Multiple sclerosis
Epilepsy
Migraine
The report contains analysis of deals by deal and product type, number of
deals year on year and the value and stage of development of these deals. It
looks at the key players and includes case studies of the key deals being made
within the five neurodegenerative diseases.
All deal data in this report are taken from the world-leading PharmaDealsR v2
Agreements database.
Table of Contents
1 Introduction to neurodegenerative diseases
1.1 Overview
1.2 Overall trends in neurodegenerative disease deals
1.2.1 Comparison with other therapy areas
1.2.2 Number of deals
1.2.3 Value of deals
1.3 Key players
1.4 Deals by territory
1.5 Impact of the ' credit crunch'
1.6 Royalties
2 Alzheimer' s disease
2.1 Overview
2.1.1 Epidemiology
2.1.2 Market size
2.1.3 Current therapies
2.1.4 Future treatments - products in development
2.2 Trends in deal making in Alzheimer' s disease
2.2.1 Overview
2.2.2 Analysis of deals by deal type
2.2.3 Deals by stage of development
2.2.4 Deals by product type
2.2.5 Key players
3 Parkinson' s Disease
3.1 Overview
3.1.1 Epidemiology
3.1.2 Market size and trends
3.1.3 Current therapies
3.1.4 Future treatments - products in development
3.2 Trends in deal making in Parkinson' s disease
3.2.1 Analysis of deals by deal type
3.2.2 Deals by stage of development
3.2.3 Deals by product type
3.2.4 Key players
4 Multiple sclerosis
4.1 Overview
4.1.1 Epidemiology
4.1.2 Market size and trends
4.1.3 Current therapies
4.1.4 Future treatments - products in development
4.2 Trends in deal making in Multiple sclerosis
4.2.1 Analysis of deals by deal type
4.2.2 Deals by stage of development
4.2.3 Deals by product type
4.2.4 Key players
5 Epilepsy
5.1 Overview
5.1.1 Epidemiology
4.1.2 Market size and trends
4.1.3 Current therapies
5.1.4 Future treatments - products in development
5.2 Trends in deal making in Epilepsy
5.2.1 Analysis of deals by deal type
5.2.2 Deals by stage of development
5.2.3 Key players
6 Migraine
6.1 Overview
6.1.1 Epidemiology
6.1.2 Market size and trends
6.1.3 Current therapies
6.1.4 Future treatments - products in development
6.2 Trends in deal making in Migraine
6.2.1 Analysis of deals by deal type
6.2.2 Deals by stage of development
6.2.3 Key players
7 Conclusions
8 Appendix 1: Alzheimer' s disease deals
8.1 J&J and Elan
8.2 TorreyPines and Eisai
8.3 Medivation and Pfizer
8.4 Myriad Genetics and Lundbeck
8.5 CoMentis and Astellas
8.6 Ablynx and Boehringer
9 Appendix 2: Parkinson' s Disease deals
9.1 Newron Pharmaceuticals and Serono
9.2 Biovail and Acadia
10 Appendix 3: Multiple sclerosis deals
10.1 Facet Biotech and Abbott
10.2 Bayer Schering and Genzyme
10.3 BioMS Medical Corp and Eli Lilly
10.4 Acorda Therapeutics and Biogen Idec
10.5 Fast Forward LLC and Merck Serono
11 Appendix 4: Epilepsy deals
11.1 Valeant and GSK
11.2 BIAL Group and Separacor
12 Appendix 4: Migraine deals
12.1 Pozen and GSK
Tables
1 Prevalence rates for dementia by age group
2 Main drugs currently marketed for AD
3 Products in Phase III development for AD
4 Selected AD deals
5 AD drugs providing symptomatic relief
6 Potentially disease-modifying AD agents
7 Diagnostics
8 Top AD dealmakers (1996 to 2009)
9 Pfizer/Wyeth late stage AD pipeline
10 Top AD principal/orginator organisations (1996 to 2009)
11 Elan' s involvement in later stage AD drugs
12 Products in Phase III development for PD
13 Top PD dealmakers (1996 to 2009)
14 Top PD principal/originator organisations (1996 to 2009)
18 Biogen Idec' s MS pipeline portfolio
19 Products in later stage development for epilepsy
20 Top epilepsy dealmakers (1996 to 2009)
21 Top epilepsy principal/originator organisations (1996 to 2009)
22 Products in later stage development for migraine
23 Top migraine dealmakers (1996 to 2009)
Figures
1 Deal intensity by therapeutic area (1996 to 2009)
2 Number of deals in five neurodegenerative disease areas (1996 to 2009)
3 Value of deals in five neurodegenerative disease areas (1996 to 2009)
3 Value of deals in five neurodegenerative disease areas (1996 to 2009)
4 Number of deals by territory in five neurodegenerative disease areas
(1996 to 2009)
5 Impact of the credit crunch on deal-making
6 Disclosed royalty rates for selected neurodegenerative diseases deals
7 2009 worldwide sales of AD drugs (US$ M)
8 total AD deals by deal type
9 Year on year analysis by deal type
10 Deal type by value
11 Number of AD deals by stage of development
12 Average value of AD deals by stage of development
13 Total PD deals by deal type
14 Year on year analysis by deal type
15 Deal type by value
16 Number of PD deals by stage of development
17 Average value of PD deals by stage of development
18 2009 worldwide sales of MS drugs (IUS$M)
19 Total MS deals by deal type
20 Year on year analysis by deal type
21 Deal type by value
22 Number of MS deals by stage of development
23 Average value of MS deals by stage of development
24 Total epilepsy deals by deal type
25 Deal type by value
26 Number of epilepsy deals by stage of development
27 Total migraine deals by deal type
28 Number of migraine deals by stage of development
29 Average value of migraine deals by stage of development
